AQS.V - Aequus Pharmaceuticals Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.1850
-0.0050 (-2.63%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Previous Close0.1900
Open0.1800
Bid0.1800 x 0
Ask0.1900 x 0
Day's Range0.1800 - 0.1850
52 Week Range0.1300 - 0.2600
Volume67,100
Avg. Volume131,478
Market Cap14.881M
Beta (3Y Monthly)0.94
PE Ratio (TTM)N/A
EPS (TTM)-0.0370
Earnings DateMay 1, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
  • GlobeNewswire18 days ago

    Aequus Closes $2.35 Million Offering of Convertible Debenture Units

    Aequus Pharmaceuticals Inc. (“Aequus” or the “Company”) (AQS.V) (AQSZF) is pleased to announce that it has closed its previously announced offering (the “Offering”) of convertible debenture units of the Company (the “Convertible Debenture Units”) at a price of $1,000 per Convertible Debenture Unit (the “Offering Price”) for aggregate gross proceeds to the Company of $2,348,000. The Offering was led by Mackie Research Capital Corporation as lead agent and sole bookrunner (the “Agent”).

  • GlobeNewswire20 days ago

    Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference on May 1, 2019

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced that its Chairman and Chief Executive Officer, Doug Janzen, will present at the eighth annual Bloom Burton & Co. Healthcare Investor Conference on Wednesday May 1st, 2019 at 2:30pm ET in Hall A at the Metro Toronto Convention Centre in Toronto, Ontario. Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products.

  • Some Aequus Pharmaceuticals (CVE:AQS) Shareholders Have Copped A Big 63% Share Price Drop
    Simply Wall St.22 days ago

    Some Aequus Pharmaceuticals (CVE:AQS) Shareholders Have Copped A Big 63% Share Price Drop

    If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough on longer term Aequus Pharmaceuticals Inc. (CVE:AQS) shareholders. So they might be feeling emotional abou...

  • GlobeNewswire24 days ago

    Aequus Announces Filing of Prospectus Supplement and an Update to Previously Announced Public Offering of Convertible Debenture Units

    Aequus Pharmaceuticals Inc. (the “Company”) (AQS.V) (AQSZF) is pleased to announce that it has filed a prospectus supplement (the “Prospectus Supplement”) to its short form base shelf prospectus dated August 15, 2017 (the “Base Shelf Prospectus”) relating to its previously announced marketed public offering of convertible debenture units of the Company (each, a “Debenture Unit”) at a price of $1,000 per Debenture Unit for gross proceeds of up to $3 million (the “Offering”). The Prospectus Supplement was filed with the securities regulatory authorities in each of the provinces of British Columbia, Alberta, Manitoba, Saskatchewan and Ontario. The confirmed terms of the Offering are that each Debenture Unit will consist of a 9.5% unsecured convertible debenture (each, a “Convertible Debenture”) with a maturity of 36 months from the date of issuance (the “Maturity Date”) and 2,380 common share purchase warrants (each, a “Warrant”), exercisable for 36 months from the date of issuance.

  • GlobeNewswire26 days ago

    Aequus Provides Financial Year End Financial Highlights

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the full year ended December 31, 2018. “2018 was our strongest year to date,” said Doug Janzen, Chairman and CEO of Aequus. “We achieved quarter over quarter revenue growth in all four quarters of the year for our commercial business, with Q4 revenue surpassing $500,000 for the first time before a one-time adjustment was applied.

  • CNW Group2 months ago

    IIROC Trading Resumption - AQS

    VANCOUVER , April 3, 2019 /CNW/ - Trading resumes in: Company: Aequus Pharmaceuticals Inc. TSX-Venture Symbol: AQS (All Issues) Resumption (ET): 11:00 AM IIROC can make a decision to impose a temporary ...

  • GlobeNewswire2 months ago

    Aequus Announces Public Offering of Convertible Debenture Units

    Aequus Pharmaceuticals Inc. (the “Company”) (AQS.V) (AQSZF) is pleased to announce that it expects to file a preliminary prospectus supplement (the “Prospectus Supplement”) to its short form base shelf prospectus dated August 15, 2017 (the “Base Shelf Prospectus”) relating to a proposed marketed public offering of convertible debenture units of the Company (each, a “Debenture Unit”) at a price of $1,000 per Debenture Unit for gross proceeds of approximately $3 million (the “Offering”). The indicative terms of the Offering are that each Debenture Unit will consist of a 9.5% unsecured convertible debenture (each, a “Convertible Debenture”) with a maturity of 36 months from the date of issuance (the “Maturity Date”) and an indicative amount of common share purchase warrants (each, a “Warrant”) representing 50% warrant coverage, exercisable for 36 months from the date of issuance.

  • CNW Group2 months ago

    IIROC Trading Halt - AQS

    VANCOUVER , April 3, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Aequus Pharmaceuticals Inc. TSX-Venture Symbol: AQS (All Issues) Reason: At the Request of the Company Pending ...

  • GlobeNewswire5 months ago

    Aequus Signs Term Sheet with European Partner for a Preservative Free Therapeutic in Ophthalmology  

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of a term sheet for an exclusive license in Canada of an undisclosed preservative free ophthalmic therapeutic with a European partner. The preservative free therapeutic is a prescription product, currently approved in certain countries in Europe. Aequus has previously met with Health Canada to receive regulatory guidance regarding this therapeutic and expects to submit an application for regulatory approval in the second half of 2019 for this product, with minimal additional analytical data required to complete the data package.

  • GlobeNewswire6 months ago

    Aequus Reports Largest Quarterly Revenue in Company History and Provides Management Update

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three and nine months ended September 30, 2018 and associated Company developments. Year to date revenue for the nine months ended September 30, 2018 of $1,173,013, a 52% increase over the same period in 2017. Decrease in net losses of 31% over the same quarter last year, and an overall 34% decrease in losses for nine months ended September 30 when compared to the same time period in 2017.

  • Is Aequus Pharmaceuticals Inc’s (CVE:AQS) CEO Being Overpaid?
    Simply Wall St.6 months ago

    Is Aequus Pharmaceuticals Inc’s (CVE:AQS) CEO Being Overpaid?

    Doug Janzen has been the CEO of Aequus Pharmaceuticals Inc (CVE:AQS) since 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then Read More...

  • What Kind Of Shareholders Own Aequus Pharmaceuticals Inc (CVE:AQS)?
    Simply Wall St.6 months ago

    What Kind Of Shareholders Own Aequus Pharmaceuticals Inc (CVE:AQS)?

    A look at the shareholders of Aequus Pharmaceuticals Inc (CVE:AQS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, Read More...

  • GlobeNewswire6 months ago

    Aequus Strengthens Clinical Experience on Strategic Advisory Board in Ophthalmology, and Adds Commercial and Regulatory Expertise

    VANCOUVER, British Columbia, Nov. 15, 2018 -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a.

  • GlobeNewswire6 months ago

    Aequus Hosts Live Webinar Demonstrating the Zepto® Capsulotomy System, Led by Dr. Ike Ahmed

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, is pleased to announce the successful presentation of a live webinar demonstrating the Zepto®  Precision Pulse Capsulotomy (“Zepto”) device’s ability to address challenging capsulotomy cases during cataract surgery. The webinar, hosted by Dr. Ike Ahmed, took place on Monday, November 12 and was attended by ophthalmologists across Canada interested in learning more about the product’s features and use within the clinic.

  • GlobeNewswire6 months ago

    Aequus forms Strategic Advisory Board in Ophthalmology, Chaired by Dr. Ike Ahmed

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced the formation of a strategic advisory board in ophthalmology with the appointment of its first two members, Dr. Ike Ahmed of the Prism Eye Institute joining as Chairman, and Dr. Rosa Braga-Mele of the University of Toronto. Aequus has formed the Advisory Board to assist in assessing and rationalizing the many ophthalmology pipeline opportunities, both in therapeutics and medical devices, available to the Company.